Provention Bio, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2016-10-04
- Employees
- 174
- Market Cap
- -
- Website
- http://www.proventionbio.com
Clinical Trials
26
Active:20
Completed:6
Trial Phases
3 Phases
Phase 1:22
Phase 2:2
Phase 3:2
Drug Approvals
1
FDA:1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (26 trials with phase data)• Click on a phase to view related trials
Phase 1
22 (84.6%)Phase 2
2 (7.7%)Phase 3
2 (7.7%)PROtocol for Coxsackievirus VaccinE in Healthy VoluNTteers
Phase 1
Completed
- Conditions
- Viral; Infection, Coxsackie(Virus)
- First Posted Date
- 2020-12-30
- Last Posted Date
- 2022-07-25
- Lead Sponsor
- Provention Bio, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT04690426
- Locations
- 🇫🇮
Clinical Research Services Turku (CRST) Oy, Turku, Finland
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of PRV-3279 in Healthy Subjects
Phase 1
Completed
- Conditions
- Safety
- First Posted Date
- 2019-05-20
- Last Posted Date
- 2023-08-28
- Lead Sponsor
- Provention Bio, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT03955666
- Locations
- 🇺🇸
Clinical site, Baltimore, Maryland, United States
Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab
Phase 3
Completed
- Conditions
- Type 1 Diabetes Mellitus
- First Posted Date
- 2019-03-15
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Provention Bio, Inc.
- Target Recruit Count
- 328
- Registration Number
- NCT03875729
- Locations
- 🇺🇸
Rady Children's Hospital-San Diego (Site 004), San Diego, California, United States
🇺🇸UCSF Medical Center (Site 001), San Francisco, California, United States
🇺🇸Diablo Clinical Research, Inc. (Site 002), Walnut Creek, California, United States
Phase 2a Study of PRV-6527 in Subjects With Moderately to Severely Active Crohn's Disease
- First Posted Date
- 2019-02-26
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- Provention Bio, Inc.
- Target Recruit Count
- 93
- Registration Number
- NCT03854305
- Locations
- 🇺🇦
Clinical Site, Zaporizhzhya, Ukraine
🇺🇦Clinical Site2, Zaporizhzhya, Ukraine
🇺🇦Clinical site, Khmelnytskyi, Ukraine
A Study to Evaluate the Safety of PRV-300 in Adult Subjects With Moderately to Severely Active Ulcerative Colitis
Phase 1
Completed
- Conditions
- Ulcerative Colitis
- First Posted Date
- 2019-02-21
- Last Posted Date
- 2020-02-13
- Lead Sponsor
- Provention Bio, Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT03849599
- Locations
- 🇺🇦
Clinical Site, Kapitanivka, Ukraine
News
No news found